Novartis wanted just one drug from MorphoSys before upping bid for whole company, document reveals
Before Novartis went all in on MorphoSys for $2.9 billion in February, the Swiss pharma giant initially wanted just one key piece from the German biotech: a late-stage small molecule drug for cancer, according to new documents published Thursday. A bid for a Phase 3 drug would fall in line